Centogene

Germany-based Centogene is a commercial-stage genetic testing and bioinformatics company that provides data-driven insights to diagnose and treat rare hereditary diseases. Its proprietary platform contains an epidemiologic, phenotypic, and genetic data repository as well as a biobank of patients’ blood samples and cell cultures collected from more than 650,000 individuals across more than 120 countries. Unlike its competitors, the company focuses on rare diseases with geographical diversity.

The company claims to have the broadest genetic testing portfolio for rare diseases with 10,000 tests that cover more than 19,000 genes in four broad categories consisting of diagnostic, predictive, carrier, and prenatal testing. Additionally, it provides support services to pharmaceuticals during the drug discovery and development process. These services include clinical trial support, patient identification, and stratification, as well as tools to accelerate drug discovery.

Key customers and partnerships

As of April 2023, the company had collaborations with more than 50 pharmaceuticals including Denali Therapeutics, Evotec AG, Orphazyme, Aldeyra Therapeutics, Chiesi Germany, and Takeda .

In June 2023, the company formed a strategic collaboration with Lifera , a biopharmaceutical company owned by the Public Investment Fund, to form a joint venture (JV) that will focus on providing multi-omic testing services in Saudi Arabia and the Gulf Cooperation Council countries.

Funding and Financials

Centogene went public in November 2019, trading on the Nasdaq Global Market under the ticker symbol “CNTG.”  It reported a revenue of EUR 147.1 million (USD 162.4  million) for 9M 2021, up 153% YoY, while net losses increased 40% YoY to EUR 34.6 million (USD 38.2 million). The company raised EUR 15 million (USD 17 million) in a private placement led by DPE Deutsche Private Equity as well a USD 45 million senior secured loan facility provided by Oxford Finance in February 2022 to enhance its service offerings available to patients, clinicians, and biopharmaceutical companies in rare metabolic and neurodegenerative disorders.